Bangladesh Dengue Death Toll Reaches 427 as October Sets Deadliest Monthly Record
Bangladesh's dengue toll has reached 427 deaths this year after October recorded 174 fatalities, the deadliest month of 2026. Hospitals in Dhaka report patients arriving in shock, while all four virus serotypes circulate and no vaccine has been introduced. Officials warn transmission will persist through November alongside the world's worst measles outbreak.
Bangladesh's dengue death toll reached 427 for the year on Sunday after eight more patients died in the 24 hours to Sunday morning, according to the Directorate General of Health Services (DGHS). A further 1,929 patients were admitted to hospital nationwide in the same period (bdnews24).
October accounted for 174 of those deaths, the highest monthly total of 2026 and an increase on the 148 recorded in September. The state news agency BSS reported the same daily figures on Sunday (BSS).
A health system under sustained pressure
In the Dhaka Division alone, 831 new patients were hospitalised between Saturday and Sunday morning. Divisional admissions for the day stood at 259 in Khulna, 257 in Chattogram, 213 in Barishal, 185 in Rajshahi, 92 in Mymensingh, 73 in Rangpur and 19 in Sylhet.
So far this year, 136,929 patients have been admitted with dengue nationwide, of whom 130,388 have been discharged after treatment, DGHS data shows.
Reuters, citing health ministry figures covering 1 January to 30 October, put the cumulative toll at 418 deaths and more than 133,000 hospital admissions (Reuters via Daily Sabah). The difference in totals reflects deaths recorded on 31 October and 1 November.
"Patients in shock"
Clinicians describe a pattern of late presentation, with many patients arriving only after serious complications have developed. At the state-run Shaheed Suhrawardy Medical College and Hospital in Dhaka, 279 dengue patients were receiving treatment after 67 new admissions in a single day.
"We are getting many patients in shock. Their blood pressure sometimes is too low to measure, and their oxygen levels are dropping," hospital director Mirza Golam Sarwar said.
Medicine specialist ABM Abdullah attributed the rise in severe cases to repeat infections combined with delays in diagnosis and treatment. People who have previously contracted dengue face a greater risk of serious illness on reinfection, he said.
The circulation of all four dengue virus serotypes is compounding the problem: a person infected with one serotype can develop more severe illness when later infected with another.
Dhakha resident Faisal Ferdous has contracted dengue three times, in 2017, 2024 and again earlier this month. "This time, both my wife and I needed hospital treatment," he said, adding that the couple fell ill shortly after spending several days at a hospital where their five-year-old son was being treated for an unrelated illness. "Every bout has been difficult. After getting it repeatedly, you become increasingly concerned about the risk of severe illness."
Bangladesh has not yet introduced a dengue vaccine, although authorities are considering vaccination as a longer-term measure.
Concurrent measles outbreak
The dengue surge is unfolding alongside the world's worst measles outbreak. More than 1,200 people have died in that outbreak, and two more children died with measles-like symptoms in the 24 hours to Sunday morning, with 1,417 suspected and confirmed cases recorded (banglanews24).
Transmission expected to persist into December
Entomologist Kabirul Bashar of Jahangirnagar University said the monthly death toll was unlikely to keep rising at the same pace, but warned that transmission would remain elevated.
"We may see some relief, but dengue is unlikely to disappear in November. Any decline is likely to be modest, with significant improvement unlikely before December," he said.
Bashar said mosquitoes would continue emerging from breeding sites created by earlier rainfall, and pointed to changing rainfall and humidity patterns — partly linked to climate change — that are extending mosquito breeding seasons and keeping Aedes mosquitoes, the primary carriers, active for longer.
Historical context
Bangladesh's worst recorded dengue outbreak was in 2023, with 321,179 hospital admissions and 1,705 deaths. More than 400 people died of the disease last year, when over 102,000 cases were reported. DGHS has maintained dengue hospitalisation and fatality records since 2000.
Verification Report
Verification Notes:CONFIRMED: Death toll of 427 and daily figures (8 deaths, 1,929 admissions) attributed to the Directorate General of Health Services and reported consistently by bdnews24 and the state news agency BSS. Year-to-date admissions (136,929) and discharges (130,388) from DGHS. October toll of 174 deaths and September's 148 from DGHS. Divisional breakdown and Dhaka Division's 831 admissions from DGHS bulletin. Historical comparison figures (2023: 321,179 admissions/1,705 deaths; 2025: 400+ deaths/102,000+ cases) from DGHS records maintained since 2000. Direct quotes from hospital director Mirza Golam Sarwar, medicine specialist ABM Abdullah, entomologist Kabirul Bashar of Jahangirnagar University, and Dhaka resident Faisal Ferdous all carried by Reuters. Measles figures (>1,200 deaths; two child deaths; 1,417 suspected/confirmed cases) from banglanews24. MINOR VARIANCE, RECONCILED IN TEXT: Reuters reported 418 cumulative deaths and 133,000+ admissions for 1 Jan–30 Oct; DGHS via bdnews24 reports 427 as of 1 Nov. The gap is explained by deaths recorded on 31 Oct and 1 Nov and is stated explicitly in the article. Reuters' October figure of 173 deaths as of 31 Oct versus DGHS' 174 as of 1 Nov follows the same one-day lag. BSS headline and body differed on whether 8 or 9 patients died in the 24-hour window; this article uses the DGHS figure of 8 as reported by bdnews24 and banglanews24. REMAINING UNCERTAINTY: Cumulative admissions differ between sources (136,929 per DGHS to 1 Nov vs 133,000+ per health ministry to 30 Oct) — these are different reporting windows rather than conflicting counts. No independent serotype surveillance data reviewed; the four-serotype circulation claim rests on specialist comment via Reuters. Vaccine status reported as of publication; no Bangladeshi regulatory decision confirmed either way. NOTE: Filed by the Editor-in-Chief, so no separate peer review was conducted. Triangulated across a national health directorate, the state news agency, and Reuters wire copy.
Sources & References
Discussion
Be the first to comment on this story.